<article article-type="case-report" dtd-version="1.4" xml:lang="en"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ther Adv Hematol</journal-id><journal-id journal-id-type="iso-abbrev">Ther Adv Hematol</journal-id><journal-id journal-id-type="pmc-domain-id">1994</journal-id><journal-id journal-id-type="pmc-domain">tah</journal-id><journal-id journal-id-type="publisher-id">TAH</journal-id><journal-title-group><journal-title>Therapeutic Advances in Hematology</journal-title></journal-title-group><issn pub-type="ppub">2040-6207</issn><issn pub-type="epub">2040-6215</issn><publisher><publisher-name>SAGE Publications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12883720</article-id><article-id pub-id-type="pmcid-ver">PMC12883720.1</article-id><article-id pub-id-type="pmcaid">12883720</article-id><article-id pub-id-type="pmcaiid">12883720</article-id><article-id pub-id-type="pmid">41668815</article-id><article-id pub-id-type="doi">10.1177/20406207261417496</article-id><article-id pub-id-type="publisher-id">10.1177_20406207261417496</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Women’s Research In: Therapeutic Advances in Hematology</subject><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></subj-group></article-categories><title-group><article-title>Early-onset de novo donor-specific anti-HLA antibodies may contribute to poor graft function following haploidentical transplantation for myelodysplastic syndrome: a rare case presentation</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="X">Xianbo</given-names></name><xref ref-type="author-notes" rid="fn1-20406207261417496">*</xref><aff id="aff1-20406207261417496">Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China</aff><aff id="aff2-20406207261417496">Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310003, Zhejiang, China</aff><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="X">Xianhui</given-names></name><xref ref-type="author-notes" rid="fn1-20406207261417496">*</xref><aff id="aff3-20406207261417496">Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China</aff><aff id="aff4-20406207261417496">Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310003, Zhejiang, China</aff><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="S">Shasha</given-names></name><xref ref-type="author-notes" rid="fn1-20406207261417496">*</xref><aff id="aff5-20406207261417496">Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China</aff><aff id="aff6-20406207261417496">Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310003, Zhejiang, China</aff><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xu</surname><given-names initials="Y">Yu</given-names></name><aff id="aff7-20406207261417496">Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China</aff><aff id="aff8-20406207261417496">Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310003, Zhejiang, China</aff><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0001-8071-8175</contrib-id><name name-style="western"><surname>Mei</surname><given-names initials="C">Chen</given-names></name><aff id="aff9-20406207261417496">Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China</aff><aff id="aff10-20406207261417496">Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310003, Zhejiang, China</aff><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Du</surname><given-names initials="F">Fengwei</given-names></name><aff id="aff11-20406207261417496">Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China</aff><aff id="aff12-20406207261417496">Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310003, Zhejiang, China</aff><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0003-0874-7806</contrib-id><name name-style="western"><surname>Ren</surname><given-names initials="Y">Yanling</given-names></name><aff id="aff13-20406207261417496">Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China</aff><aff id="aff14-20406207261417496">Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310003, Zhejiang, China</aff><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jin</surname><given-names initials="J">Jie</given-names></name><xref ref-type="corresp" rid="corresp3-20406207261417496"/><aff id="aff15-20406207261417496">Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 366 Wutong Road, Hangzhou, Zhejiang, China</aff><aff id="aff16-20406207261417496">Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310003, Zhejiang, China</aff><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0001-5603-4160</contrib-id><name name-style="western"><surname>Tong</surname><given-names initials="H">Hongyan</given-names></name><xref ref-type="corresp" rid="corresp2-20406207261417496"/><aff id="aff17-20406207261417496">Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 366 Wutong Road, Hangzhou, Zhejiang, China</aff><aff id="aff18-20406207261417496">Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310003, Zhejiang, China</aff><role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Qian</surname><given-names initials="J">Jiejing</given-names></name><xref ref-type="corresp" rid="corresp1-20406207261417496"/><aff id="aff19-20406207261417496">Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 366 Wutong Road, Hangzhou, Zhejiang, China</aff><aff id="aff20-20406207261417496">Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310003, Zhejiang, China</aff><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib></contrib-group><author-notes><corresp id="corresp1-20406207261417496">
<email>jiejingq@aliyun.com</email>
</corresp><corresp id="corresp2-20406207261417496">
<email>tonghongyan@zju.edu.cn</email>
</corresp><corresp id="corresp3-20406207261417496">
<email>jiej0503@zju.edu.cn</email>
</corresp><fn fn-type="equal" id="fn1-20406207261417496"><label>*</label><p>These authors contributed equally</p></fn></author-notes><pub-date pub-type="epub"><day>8</day><month>2</month><year>2026</year></pub-date><pub-date pub-type="collection"><year>2026</year></pub-date><volume>17</volume><issue-id pub-id-type="pmc-issue-id">503700</issue-id><elocation-id>20406207261417496</elocation-id><history><date date-type="received"><day>14</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>11</day><month>12</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>02</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>10</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-11 09:25:12.930"><day>11</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>© The Author(s), 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder content-type="sage">SAGE Publications</copyright-holder><license><ali:license_ref content-type="ccbynclicense" specific-use="textmining" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/" xmlns:xlink="http://www.w3.org/1999/xlink">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage" xmlns:xlink="http://www.w3.org/1999/xlink">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="10.1177_20406207261417496.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><abstract><p>In haploidentical hematopoietic stem cell transplantation, preexisting donor-specific anti-HLA antibodies (DSAs) in recipients have been associated with graft rejection, poor graft function (PGF), and unfavorable clinical outcomes, with relatively well-established consensus strategies for its management. However, reports on the emergence of de novo DSAs after transplantation and the corresponding therapeutic approaches remain limited. Here, we describe a case of a 14-year-old patient with myelodysplastic syndrome who developed de novo DSAs as early as day 15 post-transplantation, with a peak mean fluorescence intensity of 12,280, which was associated with PGF. To reduce DSA levels, plasma exchange combined with intravenous immunoglobulin and rituximab was administered, followed by a series of interventions including mesenchymal stem cell infusion. These measures facilitated graft function recovery, controlled transplant-related complications, and ultimately led to successful engraftment.</p></abstract><kwd-group><kwd>de novo donor-specific antibody</kwd><kwd>haploidentical transplantation</kwd><kwd>myelodysplastic syndrome</kwd><kwd>poor graft function</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2026</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="section1-20406207261417496" sec-type="intro"><title>Introduction</title><p>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a curative therapeutic option for patients with high-risk hematologic malignancies. In recent years, haploidentical hematopoietic stem cell transplantation (haplo-HSCT) has been increasingly adopted across numerous centers, particularly in the context of lacking HLA-matched donors or the need for urgent transplantation, owing to substantial advances in the prevention of graft-versus-host disease (GVHD).<sup><xref ref-type="bibr" rid="bibr1-20406207261417496">1</xref>,<xref ref-type="bibr" rid="bibr2-20406207261417496">2</xref></sup> In haplo-HSCT, preformed donor-specific anti-HLA antibodies (DSAs) present in recipients have been closely associated with graft failure and poor graft function (PGF), ultimately contributing to unfavorable post-transplant outcomes.<sup><xref ref-type="bibr" rid="bibr3-20406207261417496">3</xref>,<xref ref-type="bibr" rid="bibr4-20406207261417496">4</xref></sup> However, reports on the development of de novo DSAs are scarce, and their impact on the outcomes of haplo-HSCT remains unclear. Here, we report a case of a patient with myelodysplastic syndrome (MDS) who developed de novo DSAs on day 15 following haplo-HSCT, with a mean fluorescence intensity (MFI) reaching 12,280, which may have contributed to primary PGF. After receiving a series of treatments, the patient ultimately achieved successful engraftment. The reporting of this case conforms to the CARE guidelines for clinical case reporting.<sup>
<xref ref-type="bibr" rid="bibr5-20406207261417496">5</xref>
</sup></p></sec><sec id="section2-20406207261417496"><title>Case presentation</title><p>A 14-year-old girl presented to the Department of Hematology at the First Affiliated Hospital, Zhejiang University School of Medicine with a 4-month history of recurrent anemia. She initially experienced dizziness and fatigue without an obvious cause. On May 18, 2024, routine blood tests revealed a white blood cell (WBC) count of 2.65 × 10<sup>9</sup>/L, hemoglobin of 81 g/L, and platelet count of 181 × 10<sup>9</sup>/L. No improvement was observed after treatment with Leucogen tablets, a cysteine derivative that acts as a hematopoietic stimulator to support leukocyte recovery, and her hemoglobin level progressively declined. At Zhejiang Children’s Hospital, blood tests showed a hemoglobin level of 60 g/L. Bone marrow aspiration resulted in a dry tap, and biopsy revealed marrow fibrosis with immature megakaryocytic hyperplasia. Abdominal ultrasound showed no splenomegaly, and a definitive diagnosis could not be established. She was subsequently referred to the Children’s Hospital of Fudan University, where bone marrow aspiration again yielded poor material, with no blasts or abnormal cells detected. Whole-exome sequencing identified mutations in GATA2 (p.G268Efs*58, 49.5%), RASGRP2 (p.L518=, 46.9%), and KMT2B (c.7297+7G&gt;T, 49.0%). A chromosomal microarray revealed a full mosaic loss of chromosome 7, and bone marrow biopsy confirmed reticulin fibrosis (+++). Her father tested negative for germline GATA2 mutations. Supportive care, including red blood cell transfusions, was provided at local hospitals. On September 10, 2024, she presented to our center for further evaluation. Laboratory tests showed WBC 1.8 × 10<sup>9</sup>/L, neutrophils 0.34 × 10<sup>9</sup>/L, hemoglobin 45 g/L, and platelets 89 × 10<sup>9</sup>/L. Bone marrow evaluation indicated reduced erythroid and granulocytic precursors without blasts; flow cytometry revealed 1.93% myeloid blasts. Cytogenetic analysis demonstrated multiple clonal abnormalities: 45,XX,-7[5]/45,XX,sl,-3,+mar[2]/46,sl,+8[2]/46,XX[1]. Based on a comprehensive evaluation, she was diagnosed with myelodysplastic syndrome with low blasts (MDS-LB), classified as high-risk according to both the IPSS-R (5.5) and IPSS-M (1.33).<sup><xref ref-type="bibr" rid="bibr6-20406207261417496">6</xref>,<xref ref-type="bibr" rid="bibr7-20406207261417496">7</xref></sup> Allo-HSCT was planned using her haploidentical father as the donor. HLA typing showed a 7/12 allele match (<xref ref-type="table" rid="table1-20406207261417496">Table 1</xref>). Pre-transplant screening for class I/II anti-HLA antibodies was performed on July 24, 2024, approximately 2 months prior to transplantation, and was negative, with both class I and II antibody MFI values &lt;100. The patient was blood type B Rh-negative, and the donor was B Rh-positive.</p><table-wrap id="table1-20406207261417496" orientation="portrait" position="float"><label>Table 1.</label><caption><p>HLA typing results and de novo anti-HLA class I antibodies detected post-transplantation.</p></caption><alternatives><graphic orientation="portrait" position="float" xlink:href="10.1177_20406207261417496-table1.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Relation</th><th align="left" colspan="6" rowspan="1">HLA typing</th></tr><tr><th colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">A</th><th align="left" colspan="1" rowspan="1">B</th><th align="left" colspan="1" rowspan="1">C</th><th align="left" colspan="1" rowspan="1">DRB1</th><th align="left" colspan="1" rowspan="1">DQB1</th><th align="left" colspan="1" rowspan="1">DPB1</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Patient</td><td colspan="1" rowspan="1">11:01, 11:01</td><td colspan="1" rowspan="1">13:01, 56:03</td><td colspan="1" rowspan="1">01:02, 03:04</td><td colspan="1" rowspan="1">16:02, 12:01</td><td colspan="1" rowspan="1">05:02, 03:01</td><td colspan="1" rowspan="1">02:01, 05:01</td></tr><tr><td colspan="1" rowspan="1">Donor</td><td colspan="1" rowspan="1"><bold>24:02</bold>, 11:01</td><td colspan="1" rowspan="1"><bold>40:01</bold>, 56:03</td><td colspan="1" rowspan="1">01:02, 03:04</td><td colspan="1" rowspan="1"><bold>04:05</bold>, 12:01</td><td colspan="1" rowspan="1"><bold>04:01</bold>, 03:01</td><td colspan="1" rowspan="1"><bold>05:01</bold>, 05:01</td></tr><tr><th colspan="1" rowspan="1"/><th align="left" colspan="6" rowspan="1">MFI</th></tr><tr><th colspan="1" rowspan="1"/><th align="left" colspan="2" rowspan="1">Day +15<break/>(&gt;1000)</th><th align="left" colspan="2" rowspan="1">Day +24</th><th align="left" colspan="2" rowspan="1">Day +33</th></tr><tr><td colspan="1" rowspan="1">A*02:03</td><td colspan="2" rowspan="1">12280</td><td colspan="2" rowspan="1">590</td><td colspan="2" rowspan="1">237</td></tr><tr><td colspan="1" rowspan="1">A*03:01</td><td colspan="2" rowspan="1">11348</td><td colspan="2" rowspan="1">1292</td><td colspan="2" rowspan="1">488</td></tr><tr><td colspan="1" rowspan="1">A*02:01</td><td colspan="2" rowspan="1">11200</td><td colspan="2" rowspan="1">497</td><td colspan="2" rowspan="1">149</td></tr><tr><td colspan="1" rowspan="1">A*02:06</td><td colspan="2" rowspan="1">10973</td><td colspan="2" rowspan="1">359</td><td colspan="2" rowspan="1">153</td></tr><tr><td colspan="1" rowspan="1">A*24:03</td><td colspan="2" rowspan="1">9819</td><td colspan="2" rowspan="1">313</td><td colspan="2" rowspan="1">85</td></tr><tr><td colspan="1" rowspan="1">
<bold>A*24:02</bold>
</td><td colspan="2" rowspan="1">9183</td><td colspan="2" rowspan="1">299</td><td colspan="2" rowspan="1">94</td></tr><tr><td colspan="1" rowspan="1">A*23:01</td><td colspan="2" rowspan="1">8815</td><td colspan="2" rowspan="1">253</td><td colspan="2" rowspan="1">66</td></tr><tr><td colspan="1" rowspan="1">A*32:01</td><td colspan="2" rowspan="1">8260</td><td colspan="2" rowspan="1">465</td><td colspan="2" rowspan="1">133</td></tr><tr><td colspan="1" rowspan="1">B*49:01</td><td colspan="2" rowspan="1">6590</td><td colspan="2" rowspan="1">348</td><td colspan="2" rowspan="1">97</td></tr><tr><td colspan="1" rowspan="1">B*57:01</td><td colspan="2" rowspan="1">6258</td><td colspan="2" rowspan="1">230</td><td colspan="2" rowspan="1">66</td></tr><tr><td colspan="1" rowspan="1">B*51:02</td><td colspan="2" rowspan="1">6096</td><td colspan="2" rowspan="1">412</td><td colspan="2" rowspan="1">225</td></tr><tr><td colspan="1" rowspan="1">B*51:01</td><td colspan="2" rowspan="1">5729</td><td colspan="2" rowspan="1">357</td><td colspan="2" rowspan="1">309</td></tr><tr><td colspan="1" rowspan="1">B*59:01</td><td colspan="2" rowspan="1">4950</td><td colspan="2" rowspan="1">178</td><td colspan="2" rowspan="1">70</td></tr><tr><td colspan="1" rowspan="1">B*57:03</td><td colspan="2" rowspan="1">4898</td><td colspan="2" rowspan="1">164</td><td colspan="2" rowspan="1">69</td></tr><tr><td colspan="1" rowspan="1">A*68:01</td><td colspan="2" rowspan="1">4816</td><td colspan="2" rowspan="1">105</td><td colspan="2" rowspan="1">49</td></tr><tr><td colspan="1" rowspan="1">B*52:01</td><td colspan="2" rowspan="1">4739</td><td colspan="2" rowspan="1">248</td><td colspan="2" rowspan="1">167</td></tr><tr><td colspan="1" rowspan="1">B*15:16</td><td colspan="2" rowspan="1">3317</td><td colspan="2" rowspan="1">131</td><td colspan="2" rowspan="1">68</td></tr><tr><td colspan="1" rowspan="1">A*68:02</td><td colspan="2" rowspan="1">2643</td><td colspan="2" rowspan="1">99</td><td colspan="2" rowspan="1">68</td></tr><tr><td colspan="1" rowspan="1">B*58:01</td><td colspan="2" rowspan="1">2579</td><td colspan="2" rowspan="1">101</td><td colspan="2" rowspan="1">63</td></tr><tr><td colspan="1" rowspan="1">A*69:01</td><td colspan="2" rowspan="1">2257</td><td colspan="2" rowspan="1">57</td><td colspan="2" rowspan="1">65</td></tr><tr><td colspan="1" rowspan="1">B*53:01</td><td colspan="2" rowspan="1">1652</td><td colspan="2" rowspan="1">81</td><td colspan="2" rowspan="1">59</td></tr><tr><td colspan="1" rowspan="1">A*25:01</td><td colspan="2" rowspan="1">1594</td><td colspan="2" rowspan="1">88</td><td colspan="2" rowspan="1">1242</td></tr><tr><td colspan="1" rowspan="1">B*15:12</td><td colspan="2" rowspan="1">1517</td><td colspan="2" rowspan="1">101</td><td colspan="2" rowspan="1">71</td></tr><tr><td colspan="1" rowspan="1">B*35:01</td><td colspan="2" rowspan="1">1340</td><td colspan="2" rowspan="1">95</td><td colspan="2" rowspan="1">61</td></tr><tr><td colspan="1" rowspan="1">C*18:02</td><td colspan="2" rowspan="1">1100</td><td colspan="2" rowspan="1">71</td><td colspan="2" rowspan="1">100</td></tr><tr><td colspan="1" rowspan="1">B*50:01</td><td colspan="2" rowspan="1">1090</td><td colspan="2" rowspan="1">70</td><td colspan="2" rowspan="1">53</td></tr><tr><td colspan="1" rowspan="1">C*17:01</td><td colspan="2" rowspan="1">1078</td><td colspan="2" rowspan="1">113</td><td colspan="2" rowspan="1">91</td></tr><tr><td colspan="1" rowspan="1">B*38:01</td><td colspan="2" rowspan="1">1054</td><td colspan="2" rowspan="1">50</td><td colspan="2" rowspan="1">37</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-20406207261417496"><p>Mismatched donor alleles are underlined; de novo DSA was shown in bold.</p></fn><fn id="table-fn2-20406207261417496"><p>DSA, donor-specific anti-HLA antibodies; MFI, mean fluorescence intensity.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section3-20406207261417496"><title>Conditioning and transplant procedure</title><p>On September 14, 2024, the patient initiated conditioning for haplo-HSCT using a TBF + anti-thymocyte globulin (ATG)/post-transplant cyclophosphamide (PTCy) regimen. The conditioning lasted 8 days and consisted of thiotepa (5 mg/kg, days –8 to –7), intravenous busulfan (0.8 mg/kg every 6 h, days –7 to –5), and fludarabine (30 mg/m<sup>2</sup>, days –6 to –2). GVHD prophylaxis was administered using ATG (2 mg/kg, days –4 to –2), PTCy (25 mg/kg, days +3 and +4), cyclosporine (initiated intravenously at 2.5 mg/kg/day from Day –7 and subsequently adjusted according to trough levels to maintain 150–250 ng/ml), mycophenolate mofetil, and a short course of methotrexate. On day 0, peripheral blood stem cells collected from her father—including 10.19 × 10<sup>8</sup>/kg nucleated cells and 8.80 × 10<sup>6</sup>/kg CD34<sup>+</sup> cells—were infused.</p></sec><sec id="section4-20406207261417496"><title>Development of de novo DSAs and diagnosis of primary PGF</title><p>Based on our previous data using the TBF + ATG/PTCy conditioning regimen, the median times to neutrophil and platelet engraftment in haplo-HSCT recipients were 15 and 18 days, respectively.<sup>
<xref ref-type="bibr" rid="bibr8-20406207261417496">8</xref>
</sup> Although the TBF regimen is known to result in longer engraftment times in patients with myelofibrosis, this is generally attributable to the underlying disease itself.<sup>
<xref ref-type="bibr" rid="bibr9-20406207261417496">9</xref>
</sup> In this patient, despite the presence of reticulin fibrosis in the bone marrow, the disease course was relatively short, the diagnosis of MDS was definitive, and no splenomegaly was observed. Nevertheless, hematopoietic recovery had not occurred by day +15 post-transplant, with a WBC count of only 0.07 × 10<sup>9</sup>/L and a platelet count of 3 × 10<sup>9</sup>/L, which raised significant concern. On day +15, peripheral blood chimerism testing using short tandem repeats (STR) revealed a donor cell chimerism rate of 94.58%. Simultaneously, anti-HLA antibody screening was performed, showing strong positivity for anti-HLA class I antibodies (MFI = 12,280), while class II antibodies remained negative. Notably, a DSA against HLA-A*24:02 was identified, with an MFI of 9183, whereas all HLA antibodies were negative prior to transplantation (<xref ref-type="table" rid="table1-20406207261417496">Table 1</xref>). These findings suggested that the formation of de novo DSAs might have contributed to PGF. In response, the patient underwent three sessions of plasma exchange on days +18, +20, and +23, followed by intravenous immunoglobulin (IVIg; 1 g/kg, once) on day +24, and a single dose of rituximab (600 mg) on day +25, in an effort to reduce the DSA burden. A follow-up anti-HLA antibody test on day +24 showed a decrease in class I antibody MFI to 1292, and the A24:02 DSA level declined to 299 (<xref ref-type="table" rid="table1-20406207261417496">Table 1</xref>). On day +33, the A24:02 DSA MFI further decreased to 94 (<xref ref-type="table" rid="table1-20406207261417496">Table 1</xref>). Hematopoietic recovery was achieved on day +29, when the absolute neutrophil count (ANC) exceeded 0.5 × 10<sup>9</sup>/L, while platelet counts remained below 20 × 10<sup>9</sup>/L (<xref ref-type="fig" rid="fig1-20406207261417496">Figures 1</xref> and <xref ref-type="fig" rid="fig2-20406207261417496">2(a)</xref>).</p><fig id="fig1-20406207261417496" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Post-transplantation timeline of treatment and key clinical events.</p></caption><graphic orientation="portrait" position="float" xlink:href="10.1177_20406207261417496-fig1.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><fig id="fig2-20406207261417496" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Dynamic changes in clinical parameters following transplantation. (a) Trends in white blood cell and platelet counts after transplantation. (b) Donor chimerism analysis using short tandem repeat assays post-transplantation. (c) Pulmonary infectious lesions at different stages post-transplantation.</p></caption><graphic orientation="portrait" position="float" xlink:href="10.1177_20406207261417496-fig2.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><p>Following neutrophil engraftment, the patient was transferred out of the transplantation ward and continued inpatient care. On day +30 post-transplantation, the patient’s ANC was 0.63 × 10<sup>9</sup>/L, platelet count was 8 × 10<sup>9</sup>/L—which did not meet the criteria for platelet engraftment—and hemoglobin level was 58 g/L. A bone marrow aspiration was also performed. Morphological analysis revealed a decreased number of nucleated cells, markedly hyperplastic granulopoiesis, hypoplastic erythropoiesis, and an absence of megakaryocytes. Flow cytometric immunophenotyping revealed no immunophenotypic abnormalities, and concurrently, STR analysis demonstrated a donor chimerism rate of 99.43%. Based on these findings, a diagnosis of primary PGF was established. Notably, the patient had no other common PGF-related risk factors such as an insufficient CD34+ cell dose or splenomegaly. Therefore, the early development of de novo DSAs was considered the most likely cause of PGF. In addition, the patient was diagnosed with grade 3 hemorrhagic cystitis (detailed below), which may have contributed to persistent platelet consumption and further impaired platelet recovery. Subsequent management focused on the control of transplant-related complications, the promotion of graft function recovery, and the maintenance of stable peripheral blood cell counts.</p></sec><sec id="section5-20406207261417496"><title>Infectious complications and immune-mediated febrile episodes</title><p>With regard to infections, from day +5 post-transplantation, the patient developed recurrent fevers, with a maximum temperature (<italic toggle="yes">T</italic><sub>max</sub>) of 39.3°C. Despite multiple pathogen screening tests, no causative organisms were identified. Empirical treatment with imipenem/cilastatin led to temporary defervescence. However, between days +8 and +13, the patient again exhibited febrile episodes with <italic toggle="yes">T</italic><sub>max</sub> up to 38.9°C. On day +14, persistent high-grade fever recurred (<italic toggle="yes">T</italic><sub>max</sub> 40.2°C), and antimicrobial therapy was escalated to a combination of piperacillin-tazobactam, tigecycline, and caspofungin. Nevertheless, the fever persisted. High-sensitivity C-reactive protein peaked at 149 mg/L, while procalcitonin remained within the normal range. On day +17, metagenomic next-generation sequencing (mNGS) of peripheral blood detected <italic toggle="yes">Aspergillus flavus</italic> (77 reads) and <italic toggle="yes">Aspergillus oryzae</italic> (43 reads), and the galactomannan (GM) assay returned positive (3.42 ng/mL). Antifungal treatment was switched to voriconazole. Despite this, the patient remained febrile between days +17 and +21, with a <italic toggle="yes">T</italic><sub>max</sub> of 40.1°C. Multidisciplinary team consultation was conducted, and in consideration of the concurrent emergence of de novo DSAs, it was hypothesized that the fever was attributable to a combination of infection and immune-mediated responses. The antimicrobial regimen was further adjusted to include ceftazidime-avibactam and daptomycin, while antifungal therapy was intensified with amphotericin B plus voriconazole. Methylprednisolone was initiated at 1 mg/kg to suppress immune activation associated with infection and de novo DSAs, with tapering based on clinical response. From day +22, the patient’s fever subsided rapidly (<italic toggle="yes">T</italic><sub>max</sub> decreased to 37.8°C). A repeat mNGS on day +22 revealed a reduced sequence count for <italic toggle="yes">A. flavus</italic> (18 reads) and <italic toggle="yes">A. oryzae</italic> (3 reads). Throughout the febrile course, repeated cultures of blood, urine, stool, and sputum remained negative. On day +22, antibacterial therapy was switched to piperacillin-tazobactam. By day +23, the patient exhibited a marked increase in liver enzymes (ALT up to 2175 U/L) and direct bilirubin (up to 60 μmol/L). Drug-induced liver injury was suspected, most likely associated with voriconazole, which was subsequently discontinued while amphotericin B was continued as antifungal monotherapy. Meanwhile, hepatoprotective and choleretic therapies were administered as supportive measures. Thereafter, the patient’s liver enzyme and bilirubin levels gradually decreased. Between days +26 and +27, the patient experienced transient fever (<italic toggle="yes">T</italic><sub>max</sub> 39.6°C). At that time, neutrophil counts were rising following targeted treatment for de novo DSAs, and the fever was attributed to engraftment syndrome. Symptomatic management was effective, and the patient’s temperature gradually normalized thereafter. On day +29, chest CT revealed a lesion in the upper lobe of the left lung (<xref ref-type="fig" rid="fig2-20406207261417496">Figure 2(b)</xref>). The GM test remained positive. After consultation with infectious disease specialists, pulmonary aspergillosis was suspected, and antifungal therapy was switched to isavuconazole, with subsequent imaging showing gradual resolution of the pulmonary lesion (<xref ref-type="fig" rid="fig2-20406207261417496">Figure 2(b)</xref>).</p></sec><sec id="section6-20406207261417496"><title>Management of hemorrhagic cystitis and supportive therapies for PGF</title><p>On day +33 post-transplantation, the patient presented with gross hematuria, abdominal pain, and urinary irritation symptoms, consistent with grade 3 hemorrhagic cystitis. Ultrasound revealed bilateral renal enlargement, collecting system dilation (1.5 cm right, 0.8 cm left), right-sided hydronephrosis, and bladder wall thickening with multiple echogenic clots. Abdominal CT confirmed renal swelling, bilateral hydronephrosis (predominantly right-sided), and bladder wall thickening. Urine testing detected a high BK virus load (10<sup>7</sup> copies/mL). The patient was treated with foscarnet, intensive hydration, urine alkalinization, antispasmodics, and analgesics. On day +42, intravesical instillation of cord blood-derived exosomes was performed. One month post-transplant and after discharge from the transplant unit, the patient had achieved neutrophil engraftment but remained severely thrombocytopenic (platelet nadir 1 × 10<sup>9</sup>/L) and anemic (Hb 26 g/L), with no evidence of active infection or acute GVHD. This was considered due to a combination of PGF and hemorrhagic cystitis-related consumption. Supportive treatment included platelet and RBC transfusions, rhTPO, TPO-RAs, and 4 weekly infusions of cord blood-derived mesenchymal stem cells (MSCs, 1.0 × 10<sup>6</sup>/kg) on days +41, +48, +55, and +62. Urinary symptoms gradually improved, and hematuria resolved. On day +58, ultrasound showed reduced right hydronephrosis (0.9 cm), no left-sided dilation, and no visible bladder clots. By day +73, the patient achieved platelet engraftment, with ANC 2.22 × 10<sup>9</sup>/L and Hb 77 g/L, and was discharged in stable condition (<xref ref-type="fig" rid="fig2-20406207261417496">Figure 2(a)</xref>). She was later readmitted once, at approximately +5 months post-transplant, due to CMV viremia.</p></sec><sec id="section7-20406207261417496"><title>Post-transplant follow-up: chronic GVHD, CMV viremia, and ongoing remission</title><p>The patient underwent regular bone marrow assessments at +2, +3, +4.5, and +6 months post-transplant, all showing complete remission and &gt;99% donor chimerism by STR (<xref ref-type="fig" rid="fig2-20406207261417496">Figure 2(c)</xref>). No acute GVHD occurred. After discharge at +2.5 months, the patient was maintained on cyclosporine (50 mg/d) and tapering methylprednisolone (12 mg/d). On day +110, moderate chronic GVHD (skin, 25%–50% BSA) was diagnosed and managed with increased cyclosporine (100 mg/d) and methylprednisolone (1 mg/kg/d), resulting in rapid improvement. Immunosuppressants were then gradually tapered. At +6 months, cutaneous cGVHD progressed (&gt;50% BSA). Treatment was intensified with ruxolitinib (10 mg/d) and methylprednisolone (0.5 mg/kg/d) added to cyclosporine (50 mg/d), leading to marked improvement of the rash. Due to CMV viremia and thrombocytopenia, ruxolitinib was tapered and replaced with belumosudil (200 mg/d). The skin lesions gradually improved and stabilized, and immunosuppressants were progressively reduced. CMV viremia was first documented at approximately +5 months post-transplant (9.75 × 10<sup>5</sup> IU/mL), likely related to immunosuppressive therapy. Foscarnet treatment subsequently reduced the viral load to low-copy levels (~10<sup>2</sup> IU/mL). Further tapering of immunosuppressants is ongoing. At +8 months post-transplant, the patient remains in remission, without active GVHD or infection, and continues regular follow-up.</p></sec><sec id="section8-20406207261417496" sec-type="discussion"><title>Discussion</title><p>DSAs have emerged as one of the major challenges in haplo-HSCT in recent years. The incidence of DSAs in haploidentical HSCT ranges from 10% to 21%.<sup><xref ref-type="bibr" rid="bibr10-20406207261417496">10</xref><xref ref-type="bibr" rid="bibr11-20406207261417496"/>–<xref ref-type="bibr" rid="bibr12-20406207261417496">12</xref></sup> In a study of 345 allo-HSCT recipients, 11.3% were DSA-positive, with 31 cases involving HLA class I, 15 involving class II, and 7 involving both.<sup>
<xref ref-type="bibr" rid="bibr12-20406207261417496">12</xref>
</sup> Female recipients have significantly higher DSA incidence (86% vs 5%) and antibody levels than males,<sup>
<xref ref-type="bibr" rid="bibr10-20406207261417496">10</xref>
</sup> likely due to pregnancy-induced alloimmunization, especially in multiparous women with hematologic malignancies.<sup><xref ref-type="bibr" rid="bibr10-20406207261417496">10</xref>,<xref ref-type="bibr" rid="bibr13-20406207261417496">13</xref></sup> Transfusion is another trigger, particularly with leukocyte- or platelet-rich products, which carry a higher risk of HLA sensitization than red blood cells.<sup>
<xref ref-type="bibr" rid="bibr14-20406207261417496">14</xref>
</sup> Numerous studies have demonstrated that DSAs are closely associated with primary graft failure, PGF, GVHD, and transplant-related mortality, ultimately compromising patient survival.<sup><xref ref-type="bibr" rid="bibr12-20406207261417496">12</xref>,<xref ref-type="bibr" rid="bibr15-20406207261417496">15</xref>,<xref ref-type="bibr" rid="bibr16-20406207261417496">16</xref></sup> Compared with preexisting DSAs present in recipients prior to transplantation, de novo DSAs arising post-transplantation have received relatively less attention. De novo DSAs have been reported earlier and more extensively in solid organ transplantation. Numerous studies have identified de novo DSAs in recipients of kidney, heart, liver, and lung transplants. Similar to preexisting DSAs, de novo DSAs are also associated with higher rates of rejection and reduced survival.<sup>
<xref ref-type="bibr" rid="bibr17-20406207261417496">17</xref>
</sup></p><p>Although preexisting DSAs are relatively common in HSCT recipients, reports on post-transplant de novo DSAs remain limited. A single-center retrospective study of 303 consecutive patients who underwent their first unrelated donor allo-HSCT between January 2008 and December 2017 identified 11 DSA-positive cases (3.63%), of which 10 had preexisting DSAs, and only 1 developed a de novo DSA against DPB1*04:01 (MFI 8956) on day +21 post-transplant, resulting in primary graft rejection. DSAs were the only significant predictor of primary graft failure within 28 days (HR = 2.78; 95% CI: 1.65–4.68; <italic toggle="yes">p</italic> = 0.0001).<sup>
<xref ref-type="bibr" rid="bibr18-20406207261417496">18</xref>
</sup> Another retrospective study of 116 haplo-HSCT recipients without preexisting HLA antibodies found a de novo HLA antibody detection rate of 75.9% (88/116), with a median MFI of 2439 (range: 1033–20,162). Only 6.9% (8/116) had persistently positive de novo DSAs, all with MFI &lt;2000, and none developed graft rejection or dysfunction. This study also suggests that de novo HLA antibodies—including both DSAs and non-DSAs—can be detected as early as day +15 post-transplant, and are associated with increased risk of acute GVHD (aGVHD) and reduced disease-free survial (DFS) and overall survival (OS) in patients without pre-transplant HLA antibodies.<sup>
<xref ref-type="bibr" rid="bibr16-20406207261417496">16</xref>
</sup> Case reports have also described de novo DSA-associated graft failure or PGF in patients with chronic lymphocytic leukemia or acute myeloid leukemia following allo-HSCT.<sup><xref ref-type="bibr" rid="bibr19-20406207261417496">19</xref>,<xref ref-type="bibr" rid="bibr20-20406207261417496">20</xref></sup> In our case, a young patient with MDS developed de novo HLA class I antibodies (MFI up to 12,280) as early as day +15 post-transplant, including a DSA against HLA-A*24:02 (MFI 9183). To the best of our knowledge, no similar cases have been reported.</p><p>The mechanism of de novo DSA formation after HSCT remains unclear. Studies in animal models and solid organ transplantation suggest that donor-reactive memory B cells play a central role.<sup>
<xref ref-type="bibr" rid="bibr21-20406207261417496">21</xref>
</sup> De novo DSAs can emerge as early as day +15 post-haplo-HSCT, predominantly involving HLA class II antibodies.<sup>
<xref ref-type="bibr" rid="bibr16-20406207261417496">16</xref>
</sup> In the context of HLA-mismatched haplo-HSCT, residual host T cells may recognize donor antigens and activate recipient B cells, which then differentiate into plasma cells and produce HLA antibodies. These antibodies can bind to endothelial cells and initiate signaling cascades such as FAK/Src, ERK, PI3K, and mTORC1, leading to endothelial activation and leukocyte recruitment—processes similar to vasculopathy observed in solid organ transplantation.<sup><xref ref-type="bibr" rid="bibr22-20406207261417496">22</xref>,<xref ref-type="bibr" rid="bibr23-20406207261417496">23</xref></sup> The predominance of HLA class II antibodies may be attributed to their ability to directly recognize foreign epitopes and the high polymorphism of their encoding genes.<sup>
<xref ref-type="bibr" rid="bibr24-20406207261417496">24</xref>
</sup> Although most de novo DSAs reported after haplo-HSCT are class II antibodies, our case presented an uncommon class I DSA, which warrants further investigation. It is also important to distinguish true donor-specific alloantibody responses from transient or polyclonal antibody elevations related to cytokine release or infection. In this patient, we identified a DSA directed against HLA-A*24:02 with a high MFI (&gt;9000) on Day +15. The absence of systemic sepsis or cytokine storm during this period, together with the rapid decline in MFI following effective intervention, supports a true alloimmune process rather than a transient immune activation. Similar early-onset de novo DSAs have been reported in haploidentical transplant recipients by Wang et al.<sup>
<xref ref-type="bibr" rid="bibr16-20406207261417496">16</xref>
</sup> and Ji et al.,<sup>
<xref ref-type="bibr" rid="bibr20-20406207261417496">20</xref>
</sup> emphasizing that such antibodies, even when transient, can be clinically pathogenic and associated with poor outcomes.</p><p>Current studies indicate that both preexisting and de novo DSAs are strongly associated with an increased risk of graft failure or PGF.<sup><xref ref-type="bibr" rid="bibr12-20406207261417496">12</xref>,<xref ref-type="bibr" rid="bibr15-20406207261417496">15</xref>,<xref ref-type="bibr" rid="bibr16-20406207261417496">16</xref>,<xref ref-type="bibr" rid="bibr18-20406207261417496">18</xref><xref ref-type="bibr" rid="bibr19-20406207261417496"/>–<xref ref-type="bibr" rid="bibr20-20406207261417496">20</xref></sup> Our case highlights that de novo DSAs should be considered in patients with PGF, even if they were HLA antibody-negative prior to transplantation. In such cases, DSA testing is recommended, and desensitization should be initiated promptly once de novo DSAs are detected. Although a CD34+-selected stem cell boost is a potential therapeutic strategy for PGF, in our case, the presence of high-titer de novo DSAs made such an approach unlikely to succeed. Published data suggest that additional CD34+ infusion in the setting of persistent DSAs carries a high risk of graft failure.<sup><xref ref-type="bibr" rid="bibr25-20406207261417496">25</xref>,<xref ref-type="bibr" rid="bibr26-20406207261417496">26</xref></sup> Therefore, we prioritized desensitization and immune modulation. Reported strategies generally fall into four categories: (1) antibody removal via plasmapheresis or immunoadsorption; (2) antibody neutralization with IVIg or donor-derived HLA antigens (e.g., platelet or buffy coat transfusion); (3) inhibition of antibody production using agents such as rituximab or proteasome inhibitors, such as bortezomib; and (4) complement blockade.<sup>
<xref ref-type="bibr" rid="bibr25-20406207261417496">25</xref>
</sup> In this case, we applied three sessions of plasmapheresis combined with IVIg and rituximab, which effectively reduced de novo DSA levels. At the same time, we actively managed other potential contributors to PGF, including infection and hemorrhagic cystitis, and administered MSCs—which are known to benefit PGF<sup><xref ref-type="bibr" rid="bibr27-20406207261417496">27</xref>,<xref ref-type="bibr" rid="bibr28-20406207261417496">28</xref></sup>—together with rhTPO and TPO receptor agonists to support platelet recovery. Timely DSA detection and comprehensive interventions ultimately led to successful stem cell engraftment in this patient.</p><p>This case provides several insights relevant to both clinical practice and future research. First, initiating DSA monitoring within the first 2 weeks after haplo-HSCT can identify clinically relevant antibodies earlier than the conventionally recommended day +28 screening time point.<sup>
<xref ref-type="bibr" rid="bibr16-20406207261417496">16</xref>
</sup> Second, early initiation of desensitization therapy in combination with MSC infusion can reverse antibody-mediated PGF and restore hematopoiesis. Third, our observation that a class I DSA can cause severe graft dysfunction broadens the prevailing view that class II antibodies predominate, showing that class I DSAs can also be pathogenic. Collectively, these observations underscore the importance of early DSA surveillance, individualized management, and the development of standardized post-transplant DSA monitoring protocols in haploidentical HSCT.</p><p>In summary, although de novo DSAs are relatively uncommon after HSCT, their association with graft failure or PGF poses a serious threat to patient survival and warrants close attention. Early detection and timely intervention are critical to achieving successful engraftment. In parallel, prompt identification and management of transplant-related complications are also essential to ensure favorable clinical outcomes.</p></sec><sec id="section9-20406207261417496"><title>Limitations</title><p>This report has several limitations. First, it describes a single case, and the findings may not be generalizable to all patients undergoing haplo-HSCT. Second, mechanistic insights into how de novo DSAs contributed to PGF are limited, as functional assays were not performed. Third, although pre-transplant HLA antibody screening was negative nearly 2 months before conditioning, supportive transfusions were administered during the intervening period. Therefore, we cannot completely exclude the possibility that low-level DSAs emerged before transplantation but remained undetected at the time of conditioning. In future cases, repeat DSA testing immediately prior to transplantation, particularly when there is a delay in donor product availability or hospital admission, should be considered to detect newly formed DSAs and allow desensitization if required. Further, some therapeutic interventions, such as intravesical exosome instillation and MSC infusions, were exploratory and performed in an institutional pilot setting; their efficacy requires validation in larger prospective studies. Finally, long-term follow-up is still needed to assess the durability of engraftment, immune reconstitution, and late complications.</p></sec><sec id="section10-20406207261417496" sec-type="conclusions"><title>Conclusion</title><p>This case highlights that de novo DSAs can play a critical role in the development of primary PGF after haplo-HSCT. Timely detection and targeted immunomodulatory interventions, together with comprehensive supportive care, are essential to achieving hematopoietic recovery and favorable outcomes.</p></sec><sec id="section11-20406207261417496" sec-type="supplementary-material" specific-use="figshare"><title>Supplemental Material</title><supplementary-material content-type="local-data" id="suppl1-20406207261417496" orientation="portrait" position="float"><caption><title>sj-jpg-1-tah-10.1177_20406207261417496 – Supplemental material for Early-onset de novo donor-specific anti-HLA antibodies may contribute to poor graft function following haploidentical transplantation for myelodysplastic syndrome: a rare case presentation</title></caption><media orientation="portrait" position="float" xlink:href="sj-jpg-1-tah-10.1177_20406207261417496.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/><p>Supplemental material, sj-jpg-1-tah-10.1177_20406207261417496 for Early-onset de novo donor-specific anti-HLA antibodies may contribute to poor graft function following haploidentical transplantation for myelodysplastic syndrome: a rare case presentation by Xianbo Huang, Xianhui Wu, Shasha Wang, Yu Xu, Chen Mei, Fengwei Du, Yanling Ren, Jie Jin, Hongyan Tong and Jiejing Qian in Therapeutic Advances in Hematology</p></supplementary-material></sec></body><back><ack><p>We are deeply grateful to the patient’s legal guardians for providing consent to share the medical records for publication. We also sincerely acknowledge the commitment and professional care of the medical staff and physicians who contributed to the management and treatment of this patient.</p></ack><fn-group><fn fn-type="other"><p><bold>ORCID iDs:</bold> Chen Mei <inline-graphic xlink:href="10.1177_20406207261417496-img1.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0001-8071-8175" xmlns:xlink="http://www.w3.org/1999/xlink">https://orcid.org/0000-0001-8071-8175</ext-link></p><p>Yanling Ren <inline-graphic xlink:href="10.1177_20406207261417496-img1.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0003-0874-7806" xmlns:xlink="http://www.w3.org/1999/xlink">https://orcid.org/0000-0003-0874-7806</ext-link></p><p>Hongyan Tong <inline-graphic xlink:href="10.1177_20406207261417496-img1.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0001-5603-4160" xmlns:xlink="http://www.w3.org/1999/xlink">https://orcid.org/0000-0001-5603-4160</ext-link></p></fn><fn fn-type="supplementary-material"><p><bold>Supplemental material:</bold> Supplemental material for this article is available online.</p></fn></fn-group><sec id="section12-20406207261417496"><title>Declarations</title><fn-group><fn fn-type="other"><p><bold>Ethics approval and consent to participate:</bold> This case was reviewed and approved by the Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University (Approval No. IIT20250786A). As the patient was a 14-year-old minor, all diagnostic and therapeutic procedures, as well as participation in this study, were conducted only after obtaining written informed consent from her legal guardians, in accordance with the Declaration of Helsinki and institutional ethical standards. Written informed consent to participate in this study was obtained from the patient’s legal guardians.</p></fn><fn fn-type="other"><p><bold>Consent for publication:</bold> Written informed consent for publication of the case details and related images was obtained from the patient’s legal guardians prior to submission.</p></fn><fn fn-type="con"><p><bold>Author contributions:</bold>
<bold>Xianbo Huang:</bold> Data curation; Formal analysis; Funding acquisition; Investigation; Writing – original draft; Writing – review &amp; editing.</p><p><bold>Xianhui Wu:</bold> Formal analysis; Investigation; Writing – original draft.</p><p><bold>Shasha Wang:</bold> Data curation; Investigation; Writing – review &amp; editing.</p><p><bold>Yu Xu:</bold> Investigation; Writing – review &amp; editing.</p><p><bold>Chen Mei:</bold> Investigation; Writing – review &amp; editing.</p><p><bold>Fengwei Du:</bold> Investigation; Writing – review &amp; editing.</p><p><bold>Yanling Ren:</bold> Investigation; Writing – review &amp; editing.</p><p><bold>Jie Jin:</bold> Supervision; Writing – review &amp; editing.</p><p><bold>Hongyan Tong:</bold> Project administration; Supervision; Writing – review &amp; editing.</p><p><bold>Jiejing Qian:</bold> Supervision; Writing – review &amp; editing.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The authors received no financial support for the research, authorship, and/or publication of this article.</p></fn><fn fn-type="COI-statement"><p>The authors declare that there is no conflict of interest.</p></fn><fn fn-type="other"><p><bold>Availability of data and materials:</bold> Not applicable.</p></fn></fn-group></sec><ref-list><title>References</title><ref id="bibr1-20406207261417496"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Astigarraga</surname><given-names>CC</given-names></name>
<name name-style="western"><surname>Mpms</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Iovino</surname><given-names>L</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Haploidentical transplantation: an optimal platform for graft manipulation and cellular therapies</article-title>. <source>Blood Rev</source>
<year>2025</year>; <volume>72</volume>: <fpage>101286</fpage>.<pub-id pub-id-type="pmid">40133165</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.blre.2025.101286</pub-id></mixed-citation></ref><ref id="bibr2-20406207261417496"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Hexner</surname><given-names>EO</given-names></name>
<name name-style="western"><surname>DeFilipp</surname><given-names>Z.</given-names></name>
</person-group>
<article-title>Update in GVHD prophylaxis: novel pharmacologic and graft manipulation strategies</article-title>. <source>Am J Hematol</source>
<year>2025</year>; <volume>100</volume>(<issue>Suppl. 3</issue>): <fpage>30</fpage>–<lpage>39</lpage>.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/ajh.27597</pub-id><pub-id pub-id-type="pmid">40123545</pub-id></mixed-citation></ref><ref id="bibr3-20406207261417496"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Bailén</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Alenda</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Herruzo-Delgado</surname><given-names>B</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Results of haploidentical transplant in patients with donor-specific antibodies: a survey on behalf of the Spanish Group of Hematopoietic Transplant and Cell Therapy</article-title>. <source>Front Immunol</source>
<year>2023</year>; <volume>14</volume>: <fpage>1165759</fpage>.<pub-id pub-id-type="pmid">37304258</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.3389/fimmu.2023.1165759</pub-id><pub-id pub-id-type="pmcid">PMC10250708</pub-id></mixed-citation></ref><ref id="bibr4-20406207261417496"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Liu</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Ji</surname><given-names>X</given-names></name>
<name name-style="western"><surname>Zhu</surname><given-names>P</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Double filtration plasmapheresis combined with rituximab for donor-specific antibody desensitization in haploidentical haematopoietic stem cell transplantation</article-title>. <source>Br J Haematol</source>
<year>2023</year>; <volume>203</volume>(<issue>5</issue>): <fpage>829</fpage>–<lpage>839</lpage>.<pub-id pub-id-type="pmid">37621146</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/bjh.19046</pub-id></mixed-citation></ref><ref id="bibr5-20406207261417496"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Gagnier</surname><given-names>JJ</given-names></name>
<name name-style="western"><surname>Kienle</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name>
</person-group>, <etal>et al</etal>.; <collab>CARE Group</collab>. <article-title>The CARE guidelines: consensus-based clinical case reporting guideline development</article-title>. <source>Headache</source>
<year>2013</year>; <volume>53</volume>(<issue>10</issue>): <fpage>1541</fpage>–<lpage>1547</lpage>.<pub-id pub-id-type="pmid">24266334</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/head.12246</pub-id></mixed-citation></ref><ref id="bibr6-20406207261417496"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Khoury</surname><given-names>JD</given-names></name>
<name name-style="western"><surname>Solary</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Abla</surname><given-names>O</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms</article-title>. <source>Leukemia</source>
<year>2022</year>; <volume>36</volume>(<issue>7</issue>): <fpage>1703</fpage>–<lpage>1719</lpage>.<pub-id pub-id-type="pmid">35732831</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/s41375-022-01613-1</pub-id><pub-id pub-id-type="pmcid">PMC9252913</pub-id></mixed-citation></ref><ref id="bibr7-20406207261417496"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Greenberg</surname><given-names>PL</given-names></name>
<name name-style="western"><surname>Stone</surname><given-names>RM</given-names></name>
<name name-style="western"><surname>Abaza</surname><given-names>Y</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>NCCN guidelines<sup>®</sup> insights: myelodysplastic syndromes, version 2.2025</article-title>. <source>J Natl Compr Canc Netw</source>
<year>2025</year>; <volume>23</volume>(<issue>3</issue>): <fpage>66</fpage>–<lpage>75</lpage>.<pub-id pub-id-type="pmid">40073835</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.6004/jnccn.2025.0013</pub-id></mixed-citation></ref><ref id="bibr8-20406207261417496"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Huang</surname><given-names>X</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>X</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>S</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Thiotepa-busulfan-fludarabine conditioning as a promising approach prior to haploidentical allogeneic hematopoietic stem cell transplantation in hematological malignancies with extramedullary involvement: insights from a single center</article-title>. <source>Leuk Res</source>
<year>2024</year>; <volume>147</volume>: <fpage>107617</fpage>.<pub-id pub-id-type="pmid">39531954</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.leukres.2024.107617</pub-id></mixed-citation></ref><ref id="bibr9-20406207261417496"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Battipaglia</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Mauff</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Wendel</surname><given-names>L</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT</article-title>. <source>Bone Marrow Transplant</source>
<year>2021</year>; <volume>56</volume>(<issue>7</issue>): <fpage>1593</fpage>–<lpage>1602</lpage>.<pub-id pub-id-type="pmid">33526919</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/s41409-021-01222-z</pub-id></mixed-citation></ref><ref id="bibr10-20406207261417496"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Ciurea</surname><given-names>SO</given-names></name>
<name name-style="western"><surname>Thall</surname><given-names>PF</given-names></name>
<name name-style="western"><surname>Milton</surname><given-names>DR</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Complement-binding donor-specific anti-HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantation</article-title>. <source>Biol Blood Marrow Transplant</source>
<year>2015</year>; <volume>21</volume>(<issue>8</issue>): <fpage>1392</fpage>–<lpage>1398</lpage>.<pub-id pub-id-type="pmid">25985919</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.bbmt.2015.05.001</pub-id><pub-id pub-id-type="pmcid">PMC4506716</pub-id></mixed-citation></ref><ref id="bibr11-20406207261417496"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Yoshihara</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Maruya</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Taniguchi</surname><given-names>K</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT</article-title>. <source>Bone Marrow Transplant</source>
<year>2012</year>; <volume>47</volume>(<issue>4</issue>): <fpage>508</fpage>–<lpage>515</lpage>.<pub-id pub-id-type="pmid">21691261</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/bmt.2011.131</pub-id></mixed-citation></ref><ref id="bibr12-20406207261417496"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Chang</surname><given-names>YJ</given-names></name>
<name name-style="western"><surname>Zhao</surname><given-names>XY</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>LP</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets</article-title>. <source>J Hematol Oncol</source>
<year>2015</year>; <volume>8</volume>: <fpage>84</fpage>.<pub-id pub-id-type="pmid">26156584</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1186/s13045-015-0182-9</pub-id><pub-id pub-id-type="pmcid">PMC4496923</pub-id></mixed-citation></ref><ref id="bibr13-20406207261417496"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Ciurea</surname><given-names>SO</given-names></name>
<name name-style="western"><surname>Thall</surname><given-names>PF</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>X</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation</article-title>. <source>Blood</source>
<year>2011</year>; <volume>118</volume>(<issue>22</issue>): <fpage>5957</fpage>–<lpage>5964</lpage>.<pub-id pub-id-type="pmid">21967975</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1182/blood-2011-06-362111</pub-id><pub-id pub-id-type="pmcid">PMC3761379</pub-id></mixed-citation></ref><ref id="bibr14-20406207261417496"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Yabu</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Anderson</surname><given-names>MW</given-names></name>
<name name-style="western"><surname>Kim</surname><given-names>D</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Sensitization from transfusion in patients awaiting primary kidney transplant</article-title>. <source>Nephrol Dial Transplant</source>
<year>2013</year>; <volume>28</volume>(<issue>11</issue>): <fpage>2908</fpage>–<lpage>2918</lpage>.<pub-id pub-id-type="pmid">24009295</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1093/ndt/gft362</pub-id><pub-id pub-id-type="pmcid">PMC3811060</pub-id></mixed-citation></ref><ref id="bibr15-20406207261417496"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Krummey</surname><given-names>SM</given-names></name>
<name name-style="western"><surname>Gareau</surname><given-names>AJ.</given-names></name>
</person-group>
<article-title>Donor specific HLA antibody in hematopoietic stem cell transplantation: implications for donor selection</article-title>. <source>Front Immunol</source>
<year>2022</year>; <volume>13</volume>: <fpage>916200</fpage>.<pub-id pub-id-type="pmid">35990679</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.3389/fimmu.2022.916200</pub-id><pub-id pub-id-type="pmcid">PMC9390945</pub-id></mixed-citation></ref><ref id="bibr16-20406207261417496"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Wang</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Ji</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>L</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Posttransplant de novo DSA and NDSA affect GvHD, OS, and DFS after haplo-HSCT in patients without pre-existing HLA antibodies of hematological malignancies</article-title>. <source>Front Immunol</source>
<year>2022</year>; <volume>13</volume>: <fpage>1047200</fpage>.<pub-id pub-id-type="pmid">36532004</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.3389/fimmu.2022.1047200</pub-id><pub-id pub-id-type="pmcid">PMC9751004</pub-id></mixed-citation></ref><ref id="bibr17-20406207261417496"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Lefaucheur</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Louis</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Morris</surname><given-names>AB</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Clinical recommendations for posttransplant assessment of anti-HLA (Human Leukocyte Antigen) donor-specific antibodies: a sensitization in transplantation: assessment of risk consensus document</article-title>. <source>Am J Transplant</source>
<year>2023</year>; <volume>23</volume>(<issue>1</issue>): <fpage>115</fpage>–<lpage>132</lpage>.<pub-id pub-id-type="pmid">36695614</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.ajt.2022.11.013</pub-id></mixed-citation></ref><ref id="bibr18-20406207261417496"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Lima</surname><given-names>ACM</given-names></name>
<name name-style="western"><surname>Getz</surname><given-names>J</given-names></name>
<name name-style="western"><surname>do Amaral</surname><given-names>GB</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Donor-specific HLA antibodies are associated with graft failure and delayed hematologic recovery after unrelated donor hematopoietic cell transplantation</article-title>. <source>Transplant Cell Ther</source>
<year>2023</year>; <volume>29</volume>(<issue>8</issue>): 493.e1–493.e10.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jtct.2023.05.014</pub-id><pub-id pub-id-type="pmid">37220839</pub-id></mixed-citation></ref><ref id="bibr19-20406207261417496"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Hefazi</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Hogan</surname><given-names>WJ</given-names></name>
<name name-style="western"><surname>Wakefield</surname><given-names>LL</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The association of de novo anti-HLA-DPB1 donor-specific antibody formation and primary graft failure after allogeneic hematopoietic cell transplantation</article-title>. <source>Hum Immunol</source>
<year>2018</year>; <volume>79</volume>(<issue>12</issue>): <fpage>861</fpage>–<lpage>864</lpage>.<pub-id pub-id-type="pmid">30142360</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.humimm.2018.08.009</pub-id></mixed-citation></ref><ref id="bibr20-20406207261417496"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Ji</surname><given-names>X</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Lai</surname><given-names>X</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Post-transplant de novo anti-HLA donor specific antibodies may contribute to poor graft function after haploidentical haematopoietic stem cell transplantation</article-title>. <source>HLA</source>
<year>2024</year>; <volume>103</volume>(<issue>6</issue>): e15560.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/tan.15560</pub-id><pub-id pub-id-type="pmid">38839559</pub-id></mixed-citation></ref><ref id="bibr21-20406207261417496"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Luque</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Lúcia</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Melilli</surname><given-names>E</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Value of monitoring circulating donor-reactive memory B cells to characterize antibody-mediated rejection after kidney transplantation</article-title>. <source>Am J Transplant</source>
<year>2019</year>; <volume>19</volume>(<issue>2</issue>): <fpage>368</fpage>–<lpage>380</lpage>.<pub-id pub-id-type="pmid">30085394</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/ajt.15055</pub-id></mixed-citation></ref><ref id="bibr22-20406207261417496"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Haas</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Sis</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Racusen</surname><given-names>LC</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions</article-title>. <source>Am J Transplant</source>
<year>2014</year>; <volume>14</volume>(<issue>2</issue>): <fpage>272</fpage>–<lpage>283</lpage>.<pub-id pub-id-type="pmid">24472190</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/ajt.12590</pub-id></mixed-citation></ref><ref id="bibr23-20406207261417496"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Loupy</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Hill</surname><given-names>GS</given-names></name>
<name name-style="western"><surname>Jordan</surname><given-names>SC.</given-names></name>
</person-group>
<article-title>The impact of donor-specific anti-HLA antibodies on late kidney allograft failure</article-title>. <source>Nat Rev Nephrol</source>
<year>2012</year>; <volume>8</volume>(<issue>6</issue>): <fpage>348</fpage>–<lpage>357</lpage>.<pub-id pub-id-type="pmid">22508180</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/nrneph.2012.81</pub-id></mixed-citation></ref><ref id="bibr24-20406207261417496"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Tambur</surname><given-names>AR</given-names></name>
<name name-style="western"><surname>Claas</surname><given-names>FH.</given-names></name>
</person-group>
<article-title>HLA epitopes as viewed by antibodies: what is it all about?</article-title>
<source>Am J Transplant</source>
<year>2015</year>; <volume>15</volume>(<issue>5</issue>): <fpage>1148</fpage>–<lpage>1154</lpage>.<pub-id pub-id-type="pmid">25708017</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/ajt.13192</pub-id></mixed-citation></ref><ref id="bibr25-20406207261417496"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Ciurea</surname><given-names>SO</given-names></name>
<name name-style="western"><surname>Cao</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Fernandez-Vina</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The European society for blood and marrow transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation</article-title>. <source>Bone Marrow Transplant</source>
<year>2018</year>; <volume>53</volume>(<issue>5</issue>): <fpage>521</fpage>–<lpage>534</lpage>.<pub-id pub-id-type="pmid">29335625</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/s41409-017-0062-8</pub-id><pub-id pub-id-type="pmcid">PMC7232774</pub-id></mixed-citation></ref><ref id="bibr26-20406207261417496"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Liu</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Zhao</surname><given-names>XY</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>LP</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The impact of donor-specific anti-HLA antibody levels on primary poor graft function and graft rejection in rituximab desensitized haploidentical stem cell transplantation</article-title>. <source>HLA</source>
<year>2024</year>; <volume>103</volume>(<issue>1</issue>): e15300.<pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/tan.15300</pub-id><pub-id pub-id-type="pmid">37985437</pub-id></mixed-citation></ref><ref id="bibr27-20406207261417496"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Servais</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Baron</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Lechanteur</surname><given-names>C</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: a multicenter prospective analysis</article-title>. <source>Front Immunol</source>
<year>2023</year>; <volume>14</volume>: <fpage>1106464</fpage>.<pub-id pub-id-type="pmid">36817464</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.3389/fimmu.2023.1106464</pub-id><pub-id pub-id-type="pmcid">PMC9929549</pub-id></mixed-citation></ref><ref id="bibr28-20406207261417496"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Man</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Lu</surname><given-names>Z</given-names></name>
<name name-style="western"><surname>Yao</surname><given-names>X</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Recent advancements in poor graft function following hematopoietic stem cell transplantation</article-title>. <source>Front Immunol</source>
<year>2022</year>; <volume>13</volume>: <fpage>911174</fpage>.<pub-id pub-id-type="pmid">35720412</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.3389/fimmu.2022.911174</pub-id><pub-id pub-id-type="pmcid">PMC9202575</pub-id></mixed-citation></ref></ref-list></back></article>